Atrium Therapeutics, Inc. (RNA) Stock
Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart.
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Cash Flow (USD)
Valuation & Return Ratios
Ownership
About Atrium Therapeutics, Inc.
Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases. Founded in 2025, Atrium Therapeutics is based in San Diego, California.
Atrium Therapeutics, Inc. is led by CEO Kathleen Gallagher, headquartered in US, publicly traded since 2026.
Atrium Therapeutics, Inc. (RNA) stock trades at $8.20 with a market capitalization of $140.27M. The stock is valued at a negative price-to-earnings (P/E) ratio of -2.13, reflecting a net loss over the last twelve months, price-to-book of 0.65, price-to-sales of 5.97. Over the past 52 weeks the stock has ranged between $7.49 and $16.77, and currently trades 51.1% below its 52-week high.
On profitability, Atrium Therapeutics, Inc. generates a return on equity (ROE) of -42.90% (negative, reflecting a net loss), return on capital employed of -38.71%, an operating margin of -410.23%, a net profit margin of -396.52%.
Official website: www.atriumtherapeutics.com
Atrium Therapeutics, Inc. (RNA) — frequently asked questions
What is Atrium Therapeutics, Inc. (RNA) stock price today?
Atrium Therapeutics, Inc. (RNA) is currently trading at $8.20, up 0.49% today.
What is RNA P/E ratio?
Atrium Therapeutics, Inc.'s P/E ratio is -2.13. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.
What is RNA return on equity (ROE)?
Atrium Therapeutics, Inc.'s return on equity (ROE) is -42.90%. ROE measures net income relative to shareholders' equity. A negative ROE means the company reported a net loss over the period.
What is Atrium Therapeutics, Inc.'s market cap?
Atrium Therapeutics, Inc. has a market capitalization of $140.27M.
Does RNA pay a dividend?
Atrium Therapeutics, Inc. is not currently showing a dividend yield in our data, which means no recent cash dividend was recorded for it.
How much debt does RNA carry?
Atrium Therapeutics, Inc. has a debt-to-equity ratio of 0.01. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.
What is RNA's profit margin?
Atrium Therapeutics, Inc. reports a net profit margin of -396.52% — the share of revenue left after every cost, including tax and interest.
What sector is RNA in?
Atrium Therapeutics, Inc. is classified under Healthcare, in the Biotechnology industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.
Which exchange is RNA listed on?
Atrium Therapeutics, Inc. trades on NASDAQ under the ticker RNA.
What is RNA's 52-week range?
Over the last year Atrium Therapeutics, Inc. has traded between $7.49 and $16.77.
Related Healthcare Stocks
Popular Stocks
Screens RNA currently matches
On the figures above, Atrium Therapeutics, Inc. passes the filters for 3 of our ready-made screens, among them Debt Free Stocks Under $100, Micro Cap Stocks, Debt Free Micro Cap Stocks. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.